TIDMBXP
RNS Number : 9780I
Beximco Pharmaceuticals Ltd
30 November 2018
30 November 2018
BEXIMCO PHARMACEUTICALS LTD.
EGM Notification
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the
fast-growing manufacturer of generic pharmaceutical products and
active pharmaceutical ingredients, today announces that an
Extraordinary General Meeting of Beximco Pharmaceuticals Limited
will be held on Saturday 22 December 2018 at 10.00 a.m. at Beximco
Industrial Park, Sarabo, Kashimpur, Gazipur to amend certain
Clauses of the Memorandum of Association and Articles of
Association of the Company.
The Notice of the meeting along with the Draft Resolutions are
being mailed to the Shareholders of the Company separately.
The valued Shareholders of the Company are requested to please
attend the meeting.
By order of the Board,
Sd/-
(MOHAMMAD ASAD ULLAH, FCS)
Dated: 29 November 2018 Executive Director & Company
Secretary
NOTES:
(1) The Shareholders whose names appeared in the Share Register
of the Company or in the Depository Register on the record date
(i.e. 26 November 2018) will be entitled to attend at the
Extraordinary General Meeting.
(2) A Member entitled to attend and vote at the Extraordinary
General Meeting may appoint a Proxy to attend and vote in his/her
stead. The Proxy Form, duly stamped, must be deposited at the
Registered office of the Company, no later than 48 hours before the
time fixed for the meeting.
(3) Admission to the meeting room will be strictly on production
of the attendance slip sent with the Notice as well as verification
of signature of Member(s) and/or Proxy-holder(s).
(4) No gift or benefit in cash or kind shall be paid to the
holders of equity securities in terms of Clause (c) of the
Notification No.SEC/SRMI/2000-953/1950 dated 24 October 2000 for
attending the EGM of the Company.
For further information please visit www.beximco-pharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company
Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
Northland Capital Partners Limited (Broker)
Vadim Alexandre / Dugald J. Carlean
Tel: +44 (0)20 3861 6627
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma
manufactures and sells generic pharmaceutical formulation products
and active pharmaceutical ingredients. The Company also undertakes
contract manufacturing for multinational and leading global generic
pharmaceutical companies. The Company operates from a 23 acre site
in Dhaka and has manufacturing facilities for producing various
drugs in different delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. Ensuring
access to quality medicines is the powerful aspiration that
motivates 4,200 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others. The
Company's products are sold to retail outlets, medical institutions
and other pharmaceutical manufacturers in Bangladesh, in regional
markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and
Myanmar and in other markets overseas, principally in South East
Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia,
Philippines and Hong Kong; Africa, including South Africa,
Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central
Asia, including Azerbaijan; Middle East, including Kuwait and
Jordan; Pacific Island countries; Latin and Central American
countries; Europe, including Austria, Germany and Romania;
Australia and North America, including the USA and Canada.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOGLLFITLILAFIT
(END) Dow Jones Newswires
November 30, 2018 02:01 ET (07:01 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024